



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 May 2025
European Medicines Agency

Agenda of the Medicine Shortages (SPOC) Working Party

13 May 2025, from 09:30 to 13:30 (CEST), Teams

Chair: Monica Dias (EMA), Vice-Chair: Magdalena Rychter (GIF, Poland)

Item	Topic
1.	Welcome, declaration of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 10-11 April 2025
3.	Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)-led activities:
	a) Feedback from the MSSG Working Group (WG) on the Vulnerability Assessment Methodology
	b) Draft Recommendations of the MSSG to address anti-D immunoglobulin supply vulnerabilities
4.	Potential impact of the international situation on the supply of medicinal products for human and veterinary use to the European market:
	a) Oral status update on availability of human and veterinary medicines in MSs (only for new emerging information)
5.	Presentation from Federation of Veterinarians of Europe (FVE) :
	• Availability issues for medicinal products to treat feline infectious peritonitis (FIP)
6.	Critical shortages escalated to the SPOC Working Party:
6.1	Ongoing shortages
	a) Shortage and discontinuation of insulin containing medicinal products
	b) NovoSeven CAP (eptacog alfa) – MAH: Novo Nordisk
	c) Medicinal products from MAH Viatris
	d) Availability of sodium chloride perfusion solutions

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Topic
	e) Fluorouracil containing medicinal products
	f) Fludarabine containing medicinal products from MAH Sanofi
	g) Biltricide NAP (praziquantel) – MAH: Bayer
6.2	Status update on other critical shortages escalated to the SPOC WP (only comments to the written updates)
	a) Pegasys CAP (peginterferon alfa-2a) – MAH: Pharmaand GmbH b) Ecalta CAP (anidulafungin) and Zirabev CAP (bevacizumab) – MAH: Pfizer c) Cyanokit CAP (hydroxocobalamin) – MAH: Serb d) Medicinal products from MAH Cheplapharm e) Medicinal products containing salbutamol (inhalation use) f) Oncology medicinal products from MAH Teva g) Menopur NAP (menotropin) – MAH: Ferring h) Semintra CAP (telmisartan) – MAH: Boehringer Ingelheim Vetmedica GmbH
7.	Joint Action on shortages (CHESSMEN): Work Package 6 - Harmonisation of shortage impact assessments
8.	AOB
9.	Conclusions and next steps

Next meeting: 17 June (Teams)

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).